Galectin Therapeutics Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
GALT Nasdaq 2830 galectintherapeutics.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Galectin Therapeutics Inc.

Galectin Therapeutics to Host Virtual KOL Event to Discuss Belapectin for Treatment of MASH Cirrhosis and Portal Hypertension - Jun 10th, 2025 6:56 am
Galectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2025 and Provides Business Update - May 15th, 2025 6:00 am
Galectin Therapeutics Presented NAVIGATE Trial Results at the European Association for the Study of the Liver (EASL) 2025 Congress - May 12th, 2025 6:00 am
Galectin Therapeutics to Present at the European Association for the Study of the Liver (EASL) 2025 Congress - Apr 15th, 2025 6:00 am
Is ANI Pharmaceuticals (ANIP) Stock Outpacing Its Medical Peers This Year? - Apr 7th, 2025 7:40 am
Galectin Therapeutics Reports 2024 Financial Results and Provides Business Update - Mar 31st, 2025 6:00 am
While insiders own 20% of Galectin Therapeutics Inc. (NASDAQ:GALT), individual investors are its largest shareholders with 54% ownership - Mar 8th, 2025 6:06 am
Galectin Therapeutics Reports Significant Reduction in New Varices with Belapectin in U.S. Patient Population from the NAVIGATE Trial - Feb 18th, 2025 6:00 am
Galectin Therapeutics to Present at the 2025 MASH-TAG Conference - Jan 10th, 2025 6:00 am
Top Midday Decliners - Dec 20th, 2024 12:16 pm
Galectin Therapeutics Announces Top-Line Results of NAVIGATE Clinical Trial Evaluating Belapectin in Patients with Cirrhotic Portal Hypertension Caused by MASH - Dec 20th, 2024 6:00 am
Here's Why Galectin Therapeutics (GALT) is Poised for a Turnaround After Losing -31.83% in 4 Weeks - Dec 9th, 2024 7:35 am
Galectin Therapeutics Presents Three Abstracts at the American Association for the Study of Liver Diseases (AASLD) 2024 Liver Meeting - Nov 18th, 2024 6:00 am
Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2024 and Provides Business Update - Nov 14th, 2024 6:00 am
Galectin Therapeutics Announces Acceptance of Three Abstracts for the American Association for the Study of Liver Diseases (AASLD) 2024 Liver Meeting - Oct 15th, 2024 6:00 am
Galectin Therapeutics to Participate in the H.C. Wainwright MASH Conference - Sep 30th, 2024 6:00 am
Galectin Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference - Sep 3rd, 2024 6:30 am
Galectin Therapeutics Reports Financial Results for the Quarter Ended June 30, 2024 and Provides Business Update - Aug 13th, 2024 6:00 am
Galectin Therapeutics Appoints Khurram Jamil, M.D. to Chief Medical Officer - Aug 1st, 2024 6:00 am
Galectin Therapeutics Inc.'s (NASDAQ:GALT) largest shareholders are retail investors with 57% ownership, insiders own 20% - Jul 30th, 2024 6:39 am